Literature DB >> 2158635

Stereochemical effects of 11-OH-delta 8-tetrahydrocannabinol-dimethylheptyl to inhibit adenylate cyclase and bind to the cannabinoid receptor.

A C Howlett1, T M Champion, G H Wilken, R Mechoulam.   

Abstract

The recent preparation of the enantiomers of 11-OH-delta 8-tetrahydrocannabinol-dimethylheptyl (THC-DMH), recrystallized to absolute enantiomeric purity, has made it possible to examine the requirement for stereospecificity for the interaction of this component with the cannabinoid receptor, defined by the binding of [3H]CP-55,940 and the adenylate cyclase enzyme. The enantiomer (-)11-OH-delta 8-THC-DMH exhibited a fully efficacious and potent (IC50 = 1.8 nM) inhibition of the accumulation of cAMP in intact N18TG2 cells. The (-)enantiomer was as efficacious and potent (Kinh = 7.2 nM) as desacetyllevonantradol in inhibiting adenylate cyclase activity in membrane preparations. The (-)enantiomer was able to compete fully for the specific binding of [3H]CP-55,940 to membranes from the brain of the rat in homologous displacement studies (Ki = 234 pM). The potency ratios exhibited by the (-) to (+)enantiomers of 11-OH-delta 8-THC-DMH exceeded 1000 for each of these activities.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2158635     DOI: 10.1016/0028-3908(90)90056-w

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  18 in total

Review 1.  Efficacy in CB1 receptor-mediated signal transduction.

Authors:  Allyn C Howlett
Journal:  Br J Pharmacol       Date:  2004-08       Impact factor: 8.739

2.  Constitutive activity at the cannabinoid CB(1) receptor and behavioral responses.

Authors:  Katherine E Hanlon; Todd W Vanderah
Journal:  Methods Enzymol       Date:  2010       Impact factor: 1.600

Review 3.  Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity?

Authors:  William E Fantegrossi; Jeffery H Moran; Anna Radominska-Pandya; Paul L Prather
Journal:  Life Sci       Date:  2013-09-29       Impact factor: 5.037

Review 4.  Pharmacological and Toxicological Effects of Synthetic Cannabinoids and Their Metabolites.

Authors:  Sherrica Tai; William E Fantegrossi
Journal:  Curr Top Behav Neurosci       Date:  2017

5.  Clozapine decreases [3H] CP 55940 binding to the cannabinoid 1 receptor in the rat nucleus accumbens.

Authors:  Suresh Sundram; David Copolov; Brian Dean
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-07-02       Impact factor: 3.000

6.  Δ9-Tetrahydrocannabinol (Δ9-THC) attenuates mouse sperm motility and male fecundity.

Authors:  Daniel J Morgan; Charles H Muller; Natalia A Murataeva; Brian J Davis; Ken Mackie
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

7.  Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors.

Authors:  Z Járai; J A Wagner; K Varga; K D Lake; D R Compton; B R Martin; A M Zimmer; T I Bonner; N E Buckley; E Mezey; R K Razdan; A Zimmer; G Kunos
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

8.  Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide.

Authors:  T Bisogno; L Hanus; L De Petrocellis; S Tchilibon; D E Ponde; I Brandi; A S Moriello; J B Davis; R Mechoulam; V Di Marzo
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

9.  Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice.

Authors:  A Zimmer; A M Zimmer; A G Hohmann; M Herkenham; T I Bonner
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205

Review 10.  What we know and do not know about the cannabinoid receptor 2 (CB2).

Authors:  Anna Maria Malfitano; Sreemanti Basu; Katarzyna Maresz; Maurizio Bifulco; Bonnie N Dittel
Journal:  Semin Immunol       Date:  2014-05-28       Impact factor: 11.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.